Regular ArticlePHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)☆
References (21)
- et al.
Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography
J Pharm Sci
(1993) - et al.
NMR relaxometric investigation of Solid Lipid Nanoparticles (SLN) containing Gadolinium (III) complexes
Eur J Pharm Biopharm
(1998) - et al.
Adriamycin— an antitumour antibiotic in the treatment of neoplastic diseases
Cancer
(1973) - et al.
Activity of Adriamycin in metastatic breast cancer resistant to a combination regimen of cyclophosphamide, metotrexate, 5-fluorouracil, vincristina and prednisone
Cancer
(1974) - et al.
Adriamycin cardiotoxicity-risk factors
Cancer
(1977) - et al.
Dose response evaluation of adriamycin in human neoplasia
Cancer
(1977) Drug targeting with nanoparticles
Eur J Drug Metab Pharmacokinet
(1994)Solid lipid nanospheres from warm microemulsion
Pharm T echnol Eur
(1997)- et al.
Solid lipospheres of doxorubicin and idarubicin
Int J Pharm
(1993) - et al.
Pilocarpine hydrochloride liposome: characterization in vitro and evaluation in vivo in rabbit eye
J Microencapsulation
(1984)
There are more references available in the full text version of this article.
Cited by (115)
Solid lipid nanoparticles: An effective lipid-based technology for cancer treatment
2023, Journal of Drug Delivery Science and TechnologyA state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system
2023, Journal of Drug Delivery Science and TechnologyDevelopment of <sup>64</sup>Cu-DOX/DOX-loaded chitosan-BSA multilayered hollow microcapsules for selective lung drug delivery
2022, Journal of Drug Delivery Science and TechnologyThe Complexity of the Blood-Brain Barrier and the Concept of Age-Related Brain Targeting: Challenges and Potential of Novel Solid Lipid-Based Formulations
2022, Journal of Pharmaceutical SciencesCo-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity
2020, Biomedicine and PharmacotherapyCitation Excerpt :Moreover, lowering pH decreases the distribution coefficient (log D) of DOX, favoring its partition into the aqueous phase and, thus, increasing its release rate. Several authors have shown that the ion-pairing strategy can retain the drug encapsulated in the nanocarrier after intravenous administration, resulting in improved pharmacokinetics [25–27]. Then, the drug release would be accelerated by the relatively low pH surrounding the tumor tissue or by the acidic environment inside the endosomes and lysosomes of tumor cells, favoring the target release of DOX from the NLC [20,28].
Delivery of ionizable hydrophilic drugs based on pharmaceutical formulation of ion pairs and ionic liquids
2020, European Journal of Pharmaceutics and Biopharmaceutics
- ☆
Unspecified
Copyright © 1999 Academic Press. All rights reserved.